Effectiveness of mepolizumab in patients with severe eosinophilic asthma: In a real life study
Tuberk Toraks · 2023
DOI: 10.5578/tt.20239918 ↗Kurz gefasst
Fachartikel in der Zeitschrift Tuberk Toraks, 2023. Verfasst von İsmet Bulut und 6 weiteren Autor:innen. Beteiligte Einrichtung: Clinic of Allergy Immunology, Süreyyapaşa Chest Diseases-Thoracic Surgery Training and Research Hospital, University of Health Sciences İstanbul, Tür…. Hauptthemen laut MEDLINE: Anti-Asthmatic Agents, Asthma, Pulmonary Eosinophilia, Nasal Polyps. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Introduction
We analyzed the effects of mepolizumab treatment on symptoms, asthma attacks, pulmonary function test parameters peripheral blood eosinophil level, and percentage in patients with severe eosinophilic asthma receiving mepolizumab treatment as the baseline, sixth and twelfthmonth data. Materials and Methods: The medical records of patients diagnosed with severe eosinophilic asthma and treated with mepolizumab at our clinic were retrospectively reviewed for the period between January 2018 and December 2021. Demographic data of the patients, duration of asthma disease, comorbidities such as a nasal polyp, eosinophilic granulomatous polyangiitis, and nonsteroidal anti-inflammatory drug exacerbated respiratory disease were investigated. A comparison was made of various factors before initiating mepolizumab treatment, as well as at the sixth and twelfth month after treatment initiation. These factors include asthma control test scores, frequency of asthma attacks (including emergency admissions, hospitalizations, and intensive care admissions), peripheral blood eosinophil levels and percentages, and pulmonary function test parameters. Clinic and laboratory parameters that provide a prediction of being a responder and super responder were evaluated.
Result
A total of 21 patients were included in the study. Their mean age was 50.7 ± 11.9 years, and four (19%) were males. The mean duration of asthma diagnosis was 17.5 ±13.7 years. 14 patients (66.7%) were atopic. 4 patients (19%) had nasal polyps and four patients (19%) had NERD. Before mepolizumab, 13 (61.9%) patients had received omalizumab. The duration of receiving mepolizumab treatment was 29.2 ± 9.9 months. A statistically significant decrease was observed in both the number and percentage of eosinophils at months six and 12 (p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Clinic of Allergy Immunology, Süreyyapaşa Chest Diseases-Thoracic Surgery Training and Research Hospital, University of Health Sciences İstanbul, Türkiye.
- Clinic of Allergy Immunology, Diyarbakır Training and Research Hospital, Diyarbakır, Türkiye.
- Clinic of Allergy Immunology, Derince Training and Research Hospital, Kocaeli, Türkiye.
- Clinic of Allergy Immunology, Dr. Ersin Arslan Training and Research Hospital, Gaziantep, Türkiye.
Zitieren
APA
Bulut, İ., Yegin Katran, Z., Yavuz, D., Yıldız, A. B., Yakut, T., Örçen, C., & Mersin, S. S. (2023). Effectiveness of mepolizumab in patients with severe eosinophilic asthma: In a real life study. Tuberk Toraks. https://doi.org/10.5578/tt.20239918
Vancouver
Bulut İ, Yegin Katran Z, Yavuz D, Yıldız AB, Yakut T, Örçen C, et al. Effectiveness of mepolizumab in patients with severe eosinophilic asthma: In a real life study. Tuberk Toraks. 2023. doi:10.5578/tt.20239918
BibTeX
@article{Bulut2023,
author = {Bulut, İsmet and Yegin Katran, Zeynep and Yavuz, Dilek and Yıldız, Ali Burkan and Yakut, Tuğçe and Örçen, Cihan and Mersin, Selver Seda},
title = {Effectiveness of mepolizumab in patients with severe eosinophilic asthma: In a real life study},
journal = {Tuberk Toraks},
year = {2023},
doi = {10.5578/tt.20239918}
}
EUVIMED